Clinical Trial Finder

Inclusion Criteria:

• - Male patients or female who are not pregnant and do not plan on future pregnancy during trial participation.

• - between 30-85 years of age.

• - BMI less than or equal to 45.

• - Currently setup for an elective primary reverse total shoulder arthroplasty due to primary osteoarthritis.

• - Ability to provide informed consent to participate in the clinical trial.

• - Ability to understand and communicate in English.

• - Willingness to comply with all study procedures.

Exclusion Criteria:

• - poorly controlled comorbidities that would not allow surgical intervention such as poorly controlled diabetes (HbA1C > 8.0) renal insufficiency (eGFR <60) poorly controlled CV disease such as CHF that is NYHA class 3 and 4.

• - inability to receive the intervention including contraindications: - Cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and open and/or infected wounds at or near the treatment site.

• - patients with history of total joint infection ever or any infection in the last 6 months.

• - ASA score >3 and Outpatient Arthroplasty Risk Assessment (OARA; medical risk stratification scoring system to help determine day surgery vs.inpatient)1 score > 80.

• - previous cryoneurolysis of the suprascapular nerve-utilization of supplemental/holistic methods specifically for pain control (e.g. cannabidiol).

This will be discontinued 30 days prior to RTSA and will not be used during the duration of study participation. This will be evaluated by the Principal Investigator and study team prior to consent.

• - significant anti-coagulation usage (other than aspirin) 7 days prior to treatment.

• - CV surgery within the last 6 months.

- significant neurologic compromise (acquired or congenital/genetic) of the upper extremity to be operated on or underlying neurologic condition that would confound results in the opinion of the investigator such as a

Randomized controlled, pilot clinical trial to assess the administration of and feasibility for cyroneurolysis of the suprascapular nerve in the pre-operative setting for patients that will receive a reverse total shoulder arthroplasty (RTSA). Our primary research hypothesis is that patients who receive the intervention treatment of cryoneurolysis will experience decreased opioid usage compared to the control patient population. Primary: Assess the effectiveness and feasibility of cryoneurolysis of the suprascapular nerve performed pre-operatively for RTSA patients in reduction of the cumulative opioid consumption in the post-operative of 90 days as measured by morphine milligram equivalents (MMEs) compared to those patients who did not receive the intervention prior to a RTSA. Secondary: Assess the effectiveness of cryoneurolysis of the suprascapular nerve performed pre-operatively for RTSA patients to show: 1. a decreased pain score as measured by a Pain Assessment Documentation Tool (PADT) score. 2. increased range of motion. 3. increased patient reported outcome scores via the American Shoulder and Elbow Surgeons (ASES) shoulder score when compared to those that did not receive any intervention prior to a RTSA?

Arms

Active Comparator: Control

Those that do not receive cryoneurolysis of the suprascapular nerve prior to RTSA

Experimental: Intervention

Those that do receive cryoneurolysis of the suprascapular nerve prior to RTSA

Interventions

Device: - Cryoneurolysis

Cryoneurolysis of the suprascapular nerve

Other: - No cryoneurolysis

Control Group